Rezende Rafael M, Weiner Howard L
Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Crit Rev Immunol. 2018;38(3):207-231. doi: 10.1615/CritRevImmunol.2018026181.
Oral tolerance can be defined as an inhibition of specific immune responsiveness to subsequent parenteral injections of proteins to which an individual or animal has been previously exposed via the oral route. Multiple mechanisms of tolerance are induced by oral-fed antigens, but induction of regulatory CD4 T-cells expressing the transcription factor Foxp3 and the membrane-bound TGF-β stands out as the major players in oral tolerance. Oral antigen administration suppresses several animal models of autoimmune disease, including experimental autoimmune encephalomyelitis, uveitis, thyroiditis, myasthenia, arthritis, and diabetes, but also nonautoimmune inflammatory conditions such as asthma, atherosclerosis, graft rejection, allergy, and stroke. However, human trials have produced mixed results, and a great deal remains to be learned about the mechanisms of oral tolerance before it can be successfully applied to people. In this review, we highlight the cellular components involved in oral tolerance induction. A deep knowledge of these intricate cell interactions will pave the way for a successful application of antigen tolerance to treat autoimmune and nonautoimmune inflammatory diseases.
口服耐受可定义为对个体或动物先前经口服途径接触过的蛋白质随后进行肠胃外注射时,特异性免疫反应性受到抑制。口服抗原可诱导多种耐受机制,但诱导表达转录因子Foxp3和膜结合型转化生长因子-β(TGF-β)的调节性CD4 T细胞是口服耐受的主要机制。口服给予抗原可抑制多种自身免疫性疾病的动物模型,包括实验性自身免疫性脑脊髓炎、葡萄膜炎、甲状腺炎、重症肌无力、关节炎和糖尿病,也可抑制非自身免疫性炎症性疾病,如哮喘、动脉粥样硬化、移植排斥反应、过敏和中风。然而,人体试验结果不一,在口服耐受能够成功应用于人类之前,仍有许多关于其机制的知识有待了解。在本综述中,我们重点介绍了参与口服耐受诱导的细胞成分。深入了解这些复杂的细胞相互作用将为成功应用抗原耐受治疗自身免疫性和非自身免疫性炎症性疾病铺平道路。